MedTrace Logo

Antidepressant Maintenance in Traumatic Brain Injury

NCT00162916 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2008-06-04

No results posted yet for this study

Summary

The purpose of the study is to explore to what extent continuing the antidepressant medication citalopram (Celexa), after depression has responded to treatment, helps prevent the return of depressive symptoms in patients with recent traumatic brain injury (TBI).

Conditions

Interventions

DRUG

citalopram

20mg or 40mg, once daily, for 40 weeks

DRUG

Placebo

Cornstarch

Sponsors & Collaborators

  • Ontario Neurotrauma Foundation

    lead OTHER

Principal Investigators

  • Mark J Rapoport, MD, FRCPC · Sunnybrook Health Sciences Centre, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-05-31
Completion
2008-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162916 on ClinicalTrials.gov